Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Adynxx, Inc.
Pipeline Watch: Phase III Top-Line Results With Upadacitinib, Keytruda And Cosentyx
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Pipeline Watch: Phase III Starts With Plinabulin, Rova-T And Relugolix
Pipeline Watch is Scrip's weekly update on the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year
Venture capital investment fell $2.1bn to $7.79bn in 2016, but it was still the second-best year of VC funding for biopharma firms since 2006. Also, Venrock and Correlation closed new health care and technology funds and 10 companies raised $126.8m.
Advanced Wound Care: Untapped Opportunities
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
- Other Names / Subsidiaries
- Alliqua BioMedical, Inc.
- Alliqua, Inc.
- Celleration, Inc.
- Choice Therapeutics, Inc.
- HepaLife Technologies Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.